Charcot-Marie-Tooth Disease Type II – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Charcot-Marie-Tooth Disease Type II – Drugs In Development, 2024 report and make more profitable business decisions.
Charcot–Marie–Tooth disease (CMT) is a hereditary motor and sensory neuropathy of the peripheral nervous system characterized by progressive loss of muscle tissue and touch sensation across various parts of the body. Symptoms include Loss of touch sensation in the feet, ankles, and legs as well as in the hands, wrists, and arms occurs with various types of the disease. CMT can be diagnosed through three different forms of tests: measurement of the speed of nerve impulses (nerve conduction studies), a biopsy of the nerve, and DNA testing.
The Charcot-Marie-Tooth Disease Type II drugs in development market research report provide comprehensive information on the therapeutics under development for Charcot-Marie-Tooth Disease Type II, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Charcot-Marie-Tooth Disease Type II and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Charcot-Marie-Tooth Disease Type II | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 16 molecules, with 14 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Charcot-Marie-Tooth Disease Type II therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Charcot-Marie-Tooth Disease Type II pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Charcot-Marie-Tooth Disease Type II treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Actio Biosciences IncAcuraStem Inc
Alcyone Therapeutics Inc
Bristol-Myers Squibb Co
Mitochondria In Motion Inc
NMD Pharma AS
OliPass Corporation
Recursion Pharmaceuticals Inc
Regenacy Pharmaceuticals LLC
Starwise Therapeutics LLC
University of Pennsylvania
Washington University School of Medicine
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Charcot-Marie-Tooth Disease Type II reports